Joshua D. Tobin

Brisbane, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies.

Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 26, 2026

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.

Journal: British journal of haematology

Published: May 28, 2026

SIGN of the times: DC-SIGN and the follicular lymphoma niche.

SIGN of the times: DC-SIGN and the follicular lymphoma niche.

Journal: Blood

Published: April 30, 2026

Large B cell lymphoma microenvironment archetype profiles.

Large B cell lymphoma microenvironment archetype profiles.

Journal: Cancer cell

Published: November 15, 2024

An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early-Stage Follicular Lymphoma.

An Economic Evaluation of the TROG 99.03 Trial: Systemic Therapy After Radiotherapy in Early-Stage Follicular Lymphoma.

Journal: EJHaem

Published: August 21, 2024

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.

Journal: Blood neoplasia

Published: July 08, 2024

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Journal: American journal of hematology

Published: June 10, 2024

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Journal: EBioMedicine

Published: March 24, 2024

Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.

Journal: Internal medicine journal

Published: September 26, 2023

Epstein-Barr virus-associated lymphomas decoded.

Epstein-Barr virus-associated lymphomas decoded.

Journal: British journal of haematology

Published: July 28, 2023

Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis.

Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis.

Journal: Pathology

Published: May 04, 2022

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.

A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.

Journal: Leukemia & lymphoma

Published: July 29, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026